Mizuho Securities analyst maintained a Buy rating on Assembly Biosciences ( – ) today and set a price target of $3.00. The company’s shares opened today at $1.53. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to , Syed has an average return of -10.9% and a 43.14% success rate on recommended stocks. Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.75. The company has a one-year high of $2.42 and a one-year low of $0.82. Currently, Assembly Biosciences has an average volume of 321.9K. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves followin
$Assembly Biosciences Inc.(ASMB)$Infectious disease has definitely been on everyone’s radar for the past couple of years. And while corona made the headlines, it’s hardly the only serious pathogen out there. Hepatitis B virus (HBV) has long been known as a serious public health matter. The virus causes chronic, progressive, and severe liver disease, and while vaccines can prevent infection and transmission, there are few fully effective treatments available for patients suffering with the disease. Assembly Biosciences aims to change that situation.The company has an active research pipeline, featuring no fewer than three core inhibitor drug candidates. This is a new class of drugs, designed to interfere with the virus life cycle by blocking the virus